Zacks Investment Research·1d ago
Here's Why You Should Retain IRTC Stock in Your Portfolio for NowiRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
iRhythm is executing a volume-led growth strategy, with revenue accelerating to 20.1% YoY in 2026Q2 and gross margin expanding to 72.8%. The company achieved its first profitable quarter in 2025Q4 (net income of $5.6M) and generated $37.5M in FCF in 2026Q2, si...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.01+75.0% vs -$0.04 | $224M+2.2% vs $219M |
Q2 2026 Apr 30, 2026 | -$0.43+23.2% vs -$0.56 | $199M+2.7% vs $194M |
Q1 2026 Feb 19, 2026 | $0.17+750.0% vs $0.02 | $209M+3.5% vs $202M |
Q4 2025 Oct 30, 2025 | -$0.16+55.6% vs -$0.36 | $193M+4.4% vs $185M |
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
Hsbc Holdings PLC acquired a new position in shares of iRhythm Technologies (NASDAQ: IRTC) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,473 shares of the company's stock, valued at approximately $528,000. Other institutional investors have also recently bought and sold
California State Teachers Retirement System raised its stake in iRhythm Technologies (NASDAQ: IRTC) by 13,944.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,241,770 shares of the company's stock after purchasing an additional 5,204,446 shares during the quarter. California
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
Benchmark IRTC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for iRhythm Technologies, Inc. (IRTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $111.75 | $3.67B | -80.40 | 26.24% | -5.96% | -36.57% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $182.52 | $50.29B | 31.31 | 8.23% | 4.52% | 3.79% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — |
iRhythm Technologies, Inc. (IRTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
iRhythm Technologies, Inc. (IRTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Get notified when IRTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
iRhythm Technologies, Inc. (IRTC) stock FAQ — growth, dividends, profitability & financials explained
iRhythm Technologies, Inc. (IRTC) reported $825.3M in revenue for fiscal year 2025. This represents a 5270% increase from $15.4M in 2013.
iRhythm Technologies, Inc. (IRTC) grew revenue by 26.2% over the past year. This is strong growth.
iRhythm Technologies, Inc. (IRTC) reported a net loss of $13.9M for fiscal year 2025.
iRhythm Technologies, Inc. (IRTC) has a return on equity (ROE) of -36.6%. Negative ROE indicates the company is unprofitable.
iRhythm Technologies, Inc. (IRTC) generated $39.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
